These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19825933)

  • 21. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
    Basic-Jukic N; Kes P; Mokos I; Coric M
    Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
    [No Abstract]   [Full Text] [Related]  

  • 22. March on, not in.
    Nat Med; 2011 May; 17(5):515. PubMed ID: 21546944
    [No Abstract]   [Full Text] [Related]  

  • 23. Fabry disease: is there a role for enzyme replacement therapy?
    Mehta AB
    J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
    [No Abstract]   [Full Text] [Related]  

  • 24. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 25. Fabrazyme--recombinant protein treatment for Fabry's disease.
    Barngrover D
    J Biotechnol; 2002 May; 95(3):280-2. PubMed ID: 12080957
    [No Abstract]   [Full Text] [Related]  

  • 26. A united front.
    Nature; 2011 Apr; 472(7344):389-90. PubMed ID: 21525888
    [No Abstract]   [Full Text] [Related]  

  • 27. NIH faces marching orders on orphan drug shortage.
    Dolgin E
    Nat Med; 2011 May; 17(5):522. PubMed ID: 21546953
    [No Abstract]   [Full Text] [Related]  

  • 28. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
    Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
    [No Abstract]   [Full Text] [Related]  

  • 30. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 31. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
    Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
    Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 36. Enzyme replacement therapy for Fabry's disease.
    Waldek S; Germain DP; Wanner C; Warnock DG
    Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
    [No Abstract]   [Full Text] [Related]  

  • 37. [What is new in Fabry disease?].
    Lidove O
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
    [No Abstract]   [Full Text] [Related]  

  • 38. Enzyme replacement therapy for Fabry's disease.
    Deegan P
    Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
    [No Abstract]   [Full Text] [Related]  

  • 39. Enzyme therapy for Fabry's disease: registered for success?
    Knebelmann B; Kurschat C; Thadhani R
    Lancet; 2009 Dec; 374(9706):1950-1. PubMed ID: 19959220
    [No Abstract]   [Full Text] [Related]  

  • 40. Shire drops 'emergency' Fabry's disease drug.
    Fox JL
    Nat Biotechnol; 2012 Jun; 30(6):478. PubMed ID: 22678371
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.